VADUZ, Liechtenstein, Feb. 18, 2026 /PRNewswire/ — Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report (Q4 2025) will be published at 8:00 a.m. CET on the same day.
The presentation will be in English via webcast with teleconference:
If you wish to participate via webcast, please use the following link:
If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.
Speakers:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 43 505 20 57
[email protected] Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company’s Certified Adviser is FNCA Sweden AB, [email protected] The information was sent for publication, through the agency of the contact person set out above, on February 18, 2026 at 12:45 p.m. CET. About Implantica Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information. This information was brought to you by Cision http://news.cision.com. https://news.cision.com/implantica/r/implantica-presents-the-year-end-report–q4-2025–on-february-25-at-15-00-cet,c4309449 The following files are available for download:
- CEO Peter Forsell
- CFO Andreas Öhrnberg
- Chief Corporate Affairs Officer Nicole Pehrsson
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 43 505 20 57
[email protected] Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company’s Certified Adviser is FNCA Sweden AB, [email protected] The information was sent for publication, through the agency of the contact person set out above, on February 18, 2026 at 12:45 p.m. CET. About Implantica Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information. This information was brought to you by Cision http://news.cision.com. https://news.cision.com/implantica/r/implantica-presents-the-year-end-report–q4-2025–on-february-25-at-15-00-cet,c4309449 The following files are available for download:
Source link
Leave a Reply